Top 15 Drug Launch Superstars

FiercePharma | Tracy Staton

A year ago, FiercePharma published a list of drugs that missed when stepping on the up escalator. A heel got caught, or a sleeve. Bystanders hit the emergency stop button. For whatever reason, escalate they did not. We called it "Top 10 Drug Launch Disasters." It's still one of our most popular special reports.

This year, we wanted to take a more positive approach. So, herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Turns out, as tough as it may be to identify disasters before they happen, it's not so difficult after the fact. To go back to the escalator analogy, it's like trying to pick Will Ferrell out of an ascending crowd when he's wearing an elf costume and doing the splits.

How “Micro-Moves” Can Drive Major Health-Care Change

 

HBR Blog Network | Karen Golden-Biddle 

The complexity of today’s healthcare organizations makes it hard to change the way they do things. Conventional wisdom holds that real transformation requires bringing in consultants, undertaking large-scale and highly visible action, and jolting the organization into change. 

But there’s another, far less disruptive approach: what I call “micro-moves.” These are small and often barely visible actions and interactions that my research and that of others has found to generate real and consequential change, rather than derailing it as sweeping organizational makeovers often do. By inviting collaboration in the change process from people across the organization, micro-moves tap collective energy and build enthusiasm that is essential for driving change. 

10 αλλαγές συστήνει η επιτροπή για την ΠΦΥ

 

Γράφει ο Αιμίλιος Νεγκής 

Σε δέκα ουσιαστικά αλλαγές καταλήγει το πόρισμα της επιτροπής Σουλιώτη για την πρωτοβάθμια φροντίδα, το οποίο σήμερα κατατίθεται στον υπουργός Υγείας. 

Η Επιτροπή υπολογίζει ότι για την υποστήριξη ενός αποτελεσματικού συστήματος πρωτοβάθμιας φροντίδας υγείας απαιτείται μια μετατόπιση πόρων, έτσι ώστε οι σχετικές δαπάνες να μην υπολείπονται του 15% των δημοσίων δαπανών του συστήματος υγείας. Αυτό με τα σημερινά δεδομένα εκτιμάται ότι προσεγγίζει το 1,5 δισ. €. 

Η Επιτροπή υπογραμμίζει την ανάγκη επαναπροσδιορισμού των πόρων που διατίθενται για την ΠΦΥ στην Ελλάδα, καθώς, με τα σημερινά δεδομένα, φαίνεται πως οι ανάγκες των πολιτών έχουν υποεκτιμηθεί. Ειδικότερα, ανάμεσα στα άλλα, η επιτροπή καταλήγει στις ακόλουθες 10 προτάσεις:

Roche CEO: 'Extremely' open to talk with Novartis about teaming up

Finantial Times |  James Shotter in Zürich and Andrew Jack in London 

Roche’s chief executive has signalled openness to renewed co-operation with counterparts at his Swiss rival Novartis, in a sign of thawing relations between the two Basel-based pharmaceutical groups. 

Severin Schwan told the Financial Times in an interview: “If the right opportunity comes up, we would be extremely open to talk with Novartis as we would be with all the other players.”

His comments came just two weeks after Christoph Franz was named to replace Franz Humer as chairman of Roche, and a month after Jörg Reinhardt took over from Daniel Vasella as chairman of Novartis. 

Merck to slash 8,500 jobs in $2.5B global overhaul

 

Merck ($MRK) will cut 8,500 jobs from its R&D and commercial operations as part of a $2.5 billion global restructuring plan. The cuts come soon after Merck squeezed out its previous R&D chief to bring on Roger Perlmutter, who previously held that job at Amgen ($AMGN)--and amid major sales losses to generic competition.

The makeover also includes a shift in relocation plans. Rather than moving its headquarters to Summit, NJ, from Whitehouse Station as previously planned, the company will establish its home base in Kenilworth, on an existing Merck campus. Both the Summit facility and the Whitehouse Station headquarters will be shut down.

This restructuring is the fourth major sweep since 2008. Merck has shed many thousands of jobs and cut billions in costs over the past several years as it girded for its patent cliff--and scrambled to replace revenues drained off as key drugs lost exclusivity. One for instance: Singulair, once Merck's best-selling drug, saw sales plummet by 90% immediately upon patent expiration last year; the allergy drug brought in $618 million for the first half of this year, down from $2.8 billion for the same period of 2012. 

Germany's Bayer taps Pfizer's Olivier Brandicourt to head Bayer HealthCare

 
 

. Olivier Brandicourt

Bayer Group CEO Marijn Dekkers has high expectations for the growing Bayer HealthCare division, which makes up nearly half of the company's revenues. He has turned to a top Pfizer ($PFE) executive, 57-year-old Dr. Olivier Brandicourt, to realize those expectations. Brandicourt will assume the top job at Bayer HealthCare Nov. 1, taking over the reins from executive Wolfgang Plischke, who has been running the unit while the company found a new leader. 

"With Olivier Brandicourt we have found a strong leader with outstanding international experience and a successful track record in the healthcare industry," Dekkers said. "I am convinced that he can significantly contribute to the further growth of our healthcare business." 

Pfizer begins using ‘digital’ reps

Pfizer has begun using digital drug representatives to market medicines, leaving the decision as to whether they want to see them in doctors’ hands. It’s an unusual move that creates more of an indirect form of marketing. The firm’s new service it calls ‘Pfizerline’ has its own website with a blurb saying: “Ask Pfizer............, who can give you promotional product information at a time convenient to you. It’s simple. It’s flexible. It’s convenient. Calls can be arranged to suit your busy practice schedule.” 

 The service offers new ways for primary care doctors to talk to reps and also offers links to product information about branded medicines available in the UK. 

Market Access is Dead: Patient Access is the New Prescription for Healthcare Marketing

 

by John Glasspool 

 

Paradigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. Initially a topic for pharmaceutical companies concerned about volume, it now affects all aspects of healthcare. We believe that the current understanding of market access will undergo a fundamental shift of perspective away from a company-centered towards a patient-centered view of the problem. This article identifies several forces that challenge the current understanding of market access and lobbies for a patient-centered, comprehensive approach that aims to address the needs of all stakeholders, but primarily create value for patients: Patient Access. 

What killed market access?

 

There are four reasons why the current approach to market access is doomed to fail:

Marketer of the Year - Finalists

Aspiring Marketer
Alice Bamford TEVA UK	Neil Imrie Janssen	Nathan Tembey Lundbeck
Alison Ford  Napp Pharmaceuticals	Emma Gulliver Shire Pharmaceuticals	Thomas Renwick Roche
Jordan Millar AstraZeneca	Cyrus Colabawalla Abbvie	Simon Evans Napp Pharmaceuticals
James Burrow Lundbeck

New Marketer
Nicola Cameron Stiefel, a GSK Company	Jeannette Storey Novo Nordisk	Simon Barras Nordic Pharma
Andrew Jackson  Lundbeck	Robert Preece  Grunenthal	Angela Renshaw  Baxter Healthcare
Mark McLaughlin Abbvie	Adam Chapman  Lundbeck	Rachel Welbank Abbvie
Christina Littman Merck Serono

Senior Marketer - UK
Jenni Breadner Abbott Healthcare	Matthew Kiely  Celgene	Chris Milne Merck Serono
Niki Papadiki  TEVA UK	Gary Durkin TEVA UK	Stacey East  Baxter Healthcare
Michael Short  Merck Serono	David Styles  Merck Serono	Fiona Hooper Bayer
Hannah Watson  Abbvie	David Payne  Celgene	Jamie Cairns  Lilly
Karen Hobdell  Shire Pharmaceuticals	Andrew Smith  TEVA UK

Senior Marketer - Non UK
Nikhil Nadarkhani RPG Life Science	Eivor Orenmark Shire Pharmaceuticals, Nordic	Aurelie Lapierre Shire Pharmaceuticals, France
Laura Ameri  Shire Pharmaceuticals Italy	Simona Biondi  Shire Pharmaceuticals Italy	Nagina Elahi  Eisai BV
Julia Beba Servier	Krzysztof Ramzia  Actelion Pharma	Wojciech Kosior  Bayer
Denise Meyer  Millenium Pharmaceuticals	Audrey Laurisse Viiv Healthcare	Mohd Suhail Glenmark Pharmaceuticals
Artur Krzyzanowski  Bristol Myers Squibb

Aspiring Marketing Manager
Louise Byrne Roche	Sally Williamson Janssen	Brad Miller XenoTech
Emma Clayton  CSL Behring UK	Lance Boyd-Clark Lundbeck	Deborah Vaughan TEVA UK

 

Marketing Team
Baxter Healthcare	Shire Pharmaceuticals	Lundbeck
Napp Pharmaceuticals	Abbott Healthcare	TEVA UK 1
TEVA UK 2	A.Menarini Farmaceutica Internazionale SRL

Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023